Previous Close | 32.56 |
Open | 32.68 |
Bid | 33.29 x 800 |
Ask | 34.80 x 2200 |
Day's Range | 32.50 - 34.22 |
52 Week Range | 25.98 - 47.49 |
Volume | |
Avg. Volume | 1,490,464 |
Market Cap | 3.281B |
Beta (5Y Monthly) | 0.57 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.55 |
Earnings Date | Feb 28, 2024 - Mar 04, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 60.89 |
Subscribe to Yahoo Finance Plus to view Fair Value for CYTK
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2023 it granted stock options to purchase an aggregate of 25,350 shares of common stock to two new employees, whose employment commenced in November 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $33.48 per share, which is equal to the closing price of the Company’s common stock o
Results from COURAGE-ALS to Be Presented on December 7, 2023SOUTH SAN FRANCISCO, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations at the 34th International Symposium on ALS/MND taking place in Basel, Switzerland and online from December 6, 2023 - December 8, 2023. Oral Presentations Title: Site and Participant Perspectives on Participating in an ALS Trial Designed to Reduce Burden: COURAGE-ALSPresenter: Stacy Rudnicki, M.D., V
A few stock segments offer stronger opportunities than the healthcare stocks. It’s not an easy sector to play, but veteran investors know that these stocks, despite their famously high overhead and long product lead times, can turn on a dime and deliver a win. It’s all tied into the nature of the biopharma industry. These companies spend fortunes researching new drugs and medical techniques – but their research can pan out in the form of multi-billion addressable markets. In the meantime, invest